Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 6:27 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 308 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Depressive Disorder, Treatment-Resistant Clear all
Completed Phase 2 Interventional

FMRI of Patients Receiving IV Ketamine for Treatment Resistant Bipolar Depression

NCT06620042
View directory record Official record
Conditions
Bipolar Depression, Treatment Resistant Bipolar Depression
Interventions
Ketamine, Functional magnetic resonance imaging (fMRI)
Drug · Other
Lead sponsor
Drew Cumming
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Cleveland, Ohio • Ohio City, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 3, 2026, 6:27 PM EST
Completed Phase 3 Interventional Results available

Open-Label Safety Study of AXS-05 in Subjects With Depression

NCT04039022
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant Depression, Depression
Interventions
AXS-05 (dextromethorphan and bupropion) oral tablets
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
876 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
51
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bellflower, California + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Nov 3, 2026, 6:27 PM EST
Recruiting Phase 2 Interventional

Intravenous Ketamine for Treatment-Resistant Depression

NCT06668571
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD)
Interventions
Ketamine, Normal Saline
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 3, 2026, 6:27 PM EST
Completed Phase 4 Interventional Results available

Abilify as an Adjunctive Treatment for Refractory Depression

NCT00220636
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Aripiprazole
Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Nov 3, 2026, 6:27 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

5-hydroxytryptophan and Creatine for Treatment Resistant Depression Associated With Hypoxia in Females

NCT02356107
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
5-hydroxytryptophan and Creatine monohydrate
Drug
Lead sponsor
Perry Renshaw
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 29, 2018 · Synced Nov 3, 2026, 6:27 PM EST
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Ketamine Frequency Treatment for Major Depressive Disorder

NCT00646087
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Ketamine, Ketamine/Saline
Drug
Lead sponsor
Essentia Health
Other
Eligibility
30 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 6, 2011 · Synced Nov 3, 2026, 6:27 PM EST
Recruiting Not applicable Interventional

Coaching as an Adjunct to Ketamine Therapy for Treatment-Resistant Depression

NCT07563868
View directory record Official record
Conditions
Treatment Resistant Depression (TRD)
Interventions
Psychedelic Integration Coaching
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Nov 3, 2026, 6:27 PM EST
Completed Not applicable Interventional

Exercise in Treatment Resistant Depression (TRD): A Feasibility Study

NCT01383811
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Moderate Intensity Aerobic Exercise, Wait-list
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Nov 3, 2026, 6:27 PM EST
Completed Phase 1Phase 2 Interventional

Personalized Ultrasonic Brain Stimulation for Depression (R61)

NCT06902298
View directory record Official record
Conditions
Major Depressive Episode, Depression - Major Depressive Disorder, Treatment-Resistant Major Depressive Disorder
Interventions
LTFUS to SCC, LTFUS to ALIC
Device
Lead sponsor
Brian Mickey
Other
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 6:27 PM EST
Completed Phase 3 Interventional Results available

A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

NCT02497287
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine (Intranasal Spray), Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
16
States / cities
New Haven, Connecticut • Miami, Florida • Marietta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Nov 3, 2026, 6:27 PM EST
Completed Not applicable Interventional Results available

Accelerated Theta Burst in Treatment-Resistant Depression: A Dose Finding and Biomarker Study

NCT03680781
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Intermittent theta-burst stimulation (iTBS) delivered to the L-DLPFC, Intermittent theta-burst stimulation (iTBS) delivered to the bilateral DLPFC
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Nov 3, 2026, 6:27 PM EST
Completed Not applicable Interventional Results available

Deep Brain Stimulation (DBS) for Treatment-Resistant Depression (TRD)

NCT01898429
View directory record Official record
Conditions
Treatment Resistant Depression, Depressive Disorder, Treatment-Resistant, Depression, Bipolar
Interventions
SCC DBS
Device
Lead sponsor
Paul Holtzheimer
Other
Eligibility
22 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Nov 3, 2026, 6:27 PM EST
Completed Phase 2 Interventional Results available

Optimization of IV Ketamine for Treatment Resistant Depression

NCT00768430
View directory record Official record
Conditions
Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD)
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
21 Years to 80 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2014 · Synced Nov 3, 2026, 6:27 PM EST
Recruiting Not applicable Interventional

SAINT® Therapy for Memory Problems in Older Adults With Treatment-Resistant Depression

NCT07876908
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant, Memory Deficits
Interventions
Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT®) with the Magnus Neuromodulation System
Device
Lead sponsor
BrainHealth Solutions, Inc.
Other
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Costa Mesa, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 3, 2026, 6:27 PM EST
Not listed Phase 2 Interventional

An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)

NCT04433858
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Psilocybin
Drug
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Palo Alto, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Nov 3, 2026, 6:27 PM EST
Completed Not applicable Interventional Results available

rTMS in Treatment Resistant Depression

NCT02080507
View directory record Official record
Conditions
Depression
Interventions
Active Neuronetics rTMS stimulator, Inactive Neuronetics rTMS stimulator
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Nov 3, 2026, 6:27 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine

NCT04856124
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Intranasal esketamine
Drug
Lead sponsor
Psych Atlanta
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Marietta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Nov 3, 2026, 6:27 PM EST
Recruiting Not applicable Interventional

Maintenance rTMS for Depression (Maitr-De)

NCT06938841
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant Depression
Interventions
Transcranial Magnetic Stimulation (TMS) - Standard maintenance rTMS:, Transcranial Magnetic Stimulation (TMS) - Clustered maintenance rTMS:, Transcranial Magnetic Stimulation (TMS) -- Sham maintenance rTMS
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
San Diego, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Nov 3, 2026, 6:27 PM EST
Suspended Not applicable Interventional

Focused Ultrasound and Exosomes to Treat Depression, Anxiety, and Dementias

NCT04202770
View directory record Official record
Conditions
Refractory Depression, Anxiety Disorders, Neurodegenerative Diseases
Interventions
Exosomes
Other
Lead sponsor
Neurological Associates of West Los Angeles
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Nov 3, 2026, 6:27 PM EST
Terminated Phase 4 Interventional

Sequential Tranylcypromine (TC), TC + Dextroamphetamine and TC + Triiodothyronine for Refractory Depression

NCT00296686
View directory record Official record
Conditions
Major Depression
Interventions
Tranylcypromine, Dextroamphetamine, Triiodothyronine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2012 · Synced Nov 3, 2026, 6:27 PM EST
Completed Phase 3 Interventional

Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

NCT05624268
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Psilocybin
Drug
Lead sponsor
COMPASS Pathways
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
40
States / cities
Tuscon, Arizona • Culver City, California • Garden Grove, California + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Nov 3, 2026, 6:27 PM EST
Completed Not applicable Interventional Results available

Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder

NCT01667926
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Nov 3, 2026, 6:27 PM EST
Withdrawn Not applicable Interventional

SAINT for Treatment of Preoperative Depression to Reduce Opioid Use Following Arthroplasty

NCT04195308
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Active TBS-DLPFC, Sham TBS-DLPFC, Open label TBS-DLPFC
Device
Lead sponsor
Stanford University
Other
Eligibility
22 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Nov 3, 2026, 6:27 PM EST
Completed Not applicable Interventional Results available

Treatment Resistant Depression (Pilot)

NCT01179009
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Ketamine, Clonidine, placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Nov 3, 2026, 6:27 PM EST